SION: AscenSION CF phase IIa trial will test SION-451 plus SION-2222 in CF, starting Q1 2027
Post hoc analysis of the PreciSION CF Phase IIa trial revealed confounding due to non-adherence and lower Trikafta exposures, supporting a shift to a dual combination strategy with SION-451 plus SION-2222. The AscenSION CF phase IIa trial will begin in Q1 2027 to evaluate this approach.Based on Sio…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.